• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • exercise capacity
Riociguat Continuation After Balloon Pulmonary Angioplasty Preserves Exercise Capacity in Inoperable CTEPH: Insights from the THERAPY-HYBRID-BPA Trial
Posted inGeneral Surgery news Respiratory Specialties

Riociguat Continuation After Balloon Pulmonary Angioplasty Preserves Exercise Capacity in Inoperable CTEPH: Insights from the THERAPY-HYBRID-BPA Trial

Posted by By MedXY 09/19/2025
The THERAPY-HYBRID-BPA study demonstrates that continuing riociguat after balloon pulmonary angioplasty maintains exercise capacity in patients with inoperable chronic thromboembolic pulmonary hypertension without increasing adverse events.
Read More
Minimal Equipment Pulmonary Rehabilitation Matches Specialized Gym-Based Programs: New RCT Evidence
Posted inClinical Updates news Nursing & care Respiratory Specialties

Minimal Equipment Pulmonary Rehabilitation Matches Specialized Gym-Based Programs: New RCT Evidence

Posted by By MedXY 08/24/2025
A large randomized clinical trial demonstrates that pulmonary rehabilitation using minimal equipment is noninferior to gym-based programs with specialist equipment for improving exercise capacity and quality of life in chronic respiratory disease.
Read More
Enhancing Exercise Capacity Through Non-Invasive Vagus Nerve Stimulation: Evidence from a Randomized Controlled Trial
Posted inNeurology news Specialties

Enhancing Exercise Capacity Through Non-Invasive Vagus Nerve Stimulation: Evidence from a Randomized Controlled Trial

Posted by By MedXY 08/13/2025
A randomized trial demonstrates that non-invasive transcutaneous vagus nerve stimulation improves peak oxygen uptake and exercise performance in healthy volunteers, highlighting its potential as a safe and scalable method to boost cardiorespiratory fitness.
Read More
  • Venetoclax‑Obinutuzumab in First‑Line CLL: Efficacy Preserved in Unfit Patients — but Dose Intensity Matters
  • Long-term Outcomes in Congenital TTP: Registry Data Show Prophylactic Plasma Reduces Clinical Events but Symptoms and Product Burden Persist
  • DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results
  • DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18
  • Venetoclax plus gilteritinib shows potent preclinical activity in FLT3‑mutant BCL11B‑a lineage‑ambiguous leukemia: translational opportunities and trial design considerations
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial depression diabetes diet epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial screening sexual health sleep treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in